Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MUCINEX DM vs AMMONIUM CHLORIDE IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Guaifenesin increases respiratory tract fluid secretion to reduce mucus viscosity; dextromethorphan acts on sigma-1 receptors and NMDA receptor antagonism to suppress cough reflex.
Ammonium chloride is an acidifying agent that provides chloride ions and ammonium ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which leads to metabolic acidosis. It also directly stimulates the respiratory center and promotes diuresis by increasing the osmotic load.
Temporary relief of cough due to minor throat and bronchial irritation,Temporary relief of chest congestion and mucus buildup
Treatment of metabolic alkalosis,Urinary acidification to facilitate excretion of weak bases in poisoning,Hypochloremic states
One tablet (guaifenesin 600 mg / dextromethorphan HBr 30 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.
For metabolic alkalosis: 1-2 g intravenously every 6-12 hours as needed; maximum 6 g/day. For hypochloremic states: 1-2 g orally or intravenously 2-3 times daily.
Guaifenesin: 1-3 hours. Dextromethorphan: 3-30 hours depending on CYP2D6 phenotype; extensive metabolizers 3-8 hours, poor metabolizers 15-30 hours.
Terminal elimination half-life is approximately 2-4 hours in adults with normal hepatic and renal function. This reflects the rapid conversion of ammonium to urea in the liver and subsequent renal clearance. Half-life may be prolonged in hepatic or renal impairment.
Guaifenesin undergoes hepatic metabolism via oxidation and conjugation; dextromethorphan is metabolized by CYP2D6 to dextrorphan, an active metabolite.
Metabolized primarily in the liver via the urea cycle; ammonium ion is converted to urea, releasing hydrogen ions. The chloride ion is excreted renally.
Guaifenesin: renal (primarily as inactive metabolites, <1% unchanged). Dextromethorphan: renal (as unchanged drug and metabolites, including dextrorphan). Approximately 80% eliminated in urine as metabolites.
Renal: >99% as ammonium and chloride ions. The kidney converts ammonia to urea, which is excreted in urine. Fecal and biliary elimination are negligible.
Guaifenesin: approximately 30% to albumin. Dextromethorphan: approximately 50% to albumin and alpha-1-acid glycoprotein.
<1% bound to plasma proteins. Ammonium ions are primarily free in plasma.
Guaifenesin: 0.8-1.5 L/kg. Dextromethorphan: 5-10 L/kg (extensive tissue binding).
Approximately 0.2-0.3 L/kg, reflecting distribution mainly in extracellular fluid. Ammonium ions do not significantly penetrate cells under normal conditions.
Oral: Guaifenesin ~100% (tablet/syrup). Dextromethorphan ~11% (extensive first-pass metabolism; varies with CYP2D6 phenotype).
Oral: ~100% absorbed from the gastrointestinal tract, though first-pass hepatic metabolism (urea cycle) limits systemic availability of intact ammonium. Intravenous: 100% bioavailable.
Cr Cl 30-50 m L/min: administer every 24 hours. Cr Cl <30 m L/min: not recommended. Hemodialysis: not recommended. Peritoneal dialysis: not recommended.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-50 m L/min: reduce dose by 50% and monitor serum chloride and ammonia. For GFR >50 m L/min: no adjustment necessary.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or extend interval to every 24 hours. Child-Pugh C: not recommended.
Contraindicated in severe hepatic insufficiency (Child-Pugh class C). For Child-Pugh class B: use with caution, reduce dose by 50% and monitor ammonia levels. For Child-Pugh class A: no adjustment necessary.
Children ≥12 years: same as adult. Children 6-11 years: guaifenesin 300 mg / dextromethorphan 15 mg orally every 12 hours, not to exceed 2 doses in 24 hours. Children <6 years: not recommended.
For metabolic alkalosis: 50-100 mg/kg intravenously every 6-8 hours; maximum 2 g/day. For hypochloremic states: 75 mg/kg/day orally in divided doses.
Start at lower end of dosing range (e.g., one tablet every 24 hours) due to age-related renal and hepatic decline; monitor for CNS effects and constipation.
Start at lower end of dosing range (e.g., 1 g intravenously every 12 hours) due to age-related decline in renal function; monitor serum electrolytes and renal function closely.
None
None
Do not use for persistent/chronic cough, cough with excessive phlegm, or cough due to smoking/asthma/COPD/emphysema,Serotonin syndrome risk with MAOIs or other serotonergic drugs,Dextromethorphan abuse potential,Hypersensitivity reactions
Use with caution in patients with hepatic impairment (risk of ammonia toxicity), renal dysfunction, or respiratory acidosis. Monitor acid-base status, serum chloride, and ammonia levels. Avoid rapid infusion to prevent severe acidosis. Not for use in severe hepatic insufficiency.
Concomitant use with MAOIs or within 14 days of MAOI therapy,Hypersensitivity to any component
Severe hepatic insufficiency; severe renal failure with oliguria or anuria; primary respiratory acidosis; hypokalemia (due to risk of exacerbating potassium loss); hypersensitivity to ammonium chloride.
No significant food-drug interactions. However, alcohol may potentiate CNS effects (drowsiness/dizziness) and should be avoided.
Avoid excessive dietary intake of chloride-rich foods (e.g., table salt, processed foods) as it may affect treatment. No specific food restrictions, but maintain balanced diet as advised by physician.
FDA Category C for guaifenesin and dextromethorphan. First trimester: limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks at recommended doses. Avoid high doses of dextromethorphan due to potential serotonin reuptake inhibition and theoretical risk of fetal serotonin syndrome.
FDA Pregnancy Category C. Ammonium chloride crosses the placenta. First trimester: insufficient human data; animal studies not available; theoretical risk of fetal acidosis if maternal acidosis induced. Second/third trimester: may cause fetal acidosis, electrolyte disturbances, and potential for fetal harm if maternal overdose or pre-existing acidosis.
Guaifenesin: excreted into breast milk in small amounts; no known adverse effects in infants at maternal therapeutic doses. Dextromethorphan: likely excreted into breast milk in low concentrations; M/P ratio not established. Use caution; monitor infant for sedation, respiratory depression, or constipation.
No human data on excretion in breast milk. M/P ratio unknown. Caution advised; consider risk of infant acidosis and ammonia toxicity if exposed.
No dose adjustment required for guaifenesin or dextromethorphan during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased renal clearance) are not clinically significant at standard doses. Use the lowest effective dose for the shortest duration.
No established dose adjustment for pregnancy. Decreased GI motility and increased plasma volume may alter absorption and distribution; however, dosing should be guided by clinical response and frequent monitoring of acid-base and electrolyte status. Avoid overdosing to prevent maternal and fetal acidosis.
Mucinex DM combines guaifenesin (expectorant) and dextromethorphan (antitussive). Guaifenesin is best taken with adequate fluid intake to thin mucus. Dextromethorphan is contraindicated with MAOIs and in patients with serotonin syndrome risk. Avoid use in patients with chronic cough due to smoking, asthma, or COPD without physician guidance.
Ammonium chloride is used to treat severe metabolic alkalosis by providing chloride ions and generating mild metabolic acidosis. Monitor serum chloride, bicarbonate, and p H closely during infusion. Avoid in patients with severe hepatic impairment or renal failure. Infusion may cause local irritation; ensure proper IV access.
Take with a full glass of water to help loosen phlegm.,Do not crush or chew extended-release tablets; swallow whole.,Avoid driving or operating machinery if drowsy or dizzy.,Do not use with other cough/cold medications containing dextromethorphan.,Stop use and consult doctor if cough persists >7 days or with fever, rash, or headache.
This medication is used to correct an acid-base imbalance in your blood.,It will be given intravenously (IV) by a healthcare professional.,Report any burning, pain, or redness at the IV site immediately.,Do not consume large amounts of salt or salty foods unless directed.,Tell your doctor if you have liver or kidney disease.
No interactions on record
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MUCINEX DM vs AMMONIUM CHLORIDE IN PLASTIC CONTAINER, answered by our medical review team.
MUCINEX DM is a Expectorant/Antitussive Combination that works by Guaifenesin increases respiratory tract fluid secretion to reduce mucus viscosity; dextromethorphan acts on sigma-1 receptors and NMDA receptor antagonism to suppress cough reflex.. AMMONIUM CHLORIDE IN PLASTIC CONTAINER is a Expectorant/Systemic Acidifier that works by Ammonium chloride is an acidifying agent that provides chloride ions and ammonium ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which leads to metabolic acidosis. It also directly stimulates the respiratory center and promotes diuresis by increasing the osmotic load.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MUCINEX DM and AMMONIUM CHLORIDE IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MUCINEX DM is: One tablet (guaifenesin 600 mg / dextromethorphan HBr 30 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.. The standard adult dose of AMMONIUM CHLORIDE IN PLASTIC CONTAINER is: For metabolic alkalosis: 1-2 g intravenously every 6-12 hours as needed; maximum 6 g/day. For hypochloremic states: 1-2 g orally or intravenously 2-3 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MUCINEX DM and AMMONIUM CHLORIDE IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MUCINEX DM is classified as Category C. FDA Category C for guaifenesin and dextromethorphan. First trimester: limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and. AMMONIUM CHLORIDE IN PLASTIC CONTAINER is classified as Category C. FDA Pregnancy Category C. Ammonium chloride crosses the placenta. First trimester: insufficient human data; animal studies not available; theoretical risk of fetal acidosis if mate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.